Redeye comments on Avensia’s Q1 2026 report, showing a stronger than expected EBIT and with IM now c...
* Market remains soft, but Ework is taking decisive actions on costs * We raise '26e-'28e adj.
Sales and order intake in the first quarter remained slow, as expected.
Equity story unchanged. The prolonged Strait of Hormuz closure and related fuel-supply risk warrant ...
Redeye updates its estimates and valuation after Collaxio's Q1 2026 report.
* Adjusted EBIT turned negative on sales miss * But a major layoffs could lift cons '27e-'28e EBIT (...
Redeye is positive about the discovery of abscopal effects in non-treated lesions in basal cell carc...
* Solid lettings in the wake of Nasdaq, but timing uncertain * Estimates hit by higher interest rate...
Redeye provides an initial take following the release of Optomed’s Q1 2026 report.
Dynavox utvecklar kommunikationshjälpmedel för personer med nedsatt talförmåga.
On Tuesday, the German government has published the draft legislations for the FahrschModVO (driving...
QBY will release its Q1’26 figures next Monday. Given the still challenging macroeconomic and geopol...
G5 reported a softer-than-expected quarter, with organic growth of -11% y/y (we had -4%), with large...
CapMan’s Q1 fee income of EUR 15.9m grew 22% y/y and was 7% ahead of our estimate of EUR 14.
CapMan's Q1 performance can be called broadly in line.
Redeye updates its estimates and valuation following Tradedoubler's Q1 2026 report, which came in br...
Redeye comments on Medivir's Q1 report 2026. The phase II study of fostrox is set up to start with t...
Operational volumes were weaker than we expected in Q1, and we therefore lower our net sales estimat...
NoHo Partners' Q1 results fell below Vara Research consensus, mainly owing to the prevailing challen...
* Cole & Son management changes weigh on Q1 EBITA * We expect Cole & Son to move toward hospitality ...
